The data presented highlight the need for standardized antibodies for analysis of clinical material if YB-1 is to gain acceptance as a reliable prognostic marker, as has been done for the prognostic determination of the ER and HER2 immunostaining on breast cancers [42], [43]. Here, ERBB2 is linked to breast carcinoma.